Article

Quantifying the Dual Value and Governance Risks of Early Access Programs in Oncology: A Single-Centre Analysis and National Policy Framework

2026-03-30

Abstract excerpt

<title>Abstract</title> <p> <bold>Background</bold> Early Access Programs (EAPs) and Named Patient Programs (NPPs) in Italy, governed by the Decreto Lorenzin (2017), are the primary route through which oncology patients access innovative therapies pending reimbursement by the Agenzia Italiana del Farmaco (AIFA). Their institutional value has not been systematically quantified, and key governance gaps remain for...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ab6a703c-48da-5443-b439-780a85f1a67e
DOI: 10.21203/rs.3.rs-9212433/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Quantifying the Dual Value and Governance Risks of Early Access Programs in Oncology: A Single-Centre Analysis and National Policy FrameworkDOI 10.21203/rs.3.rs-9212433/v1Read

The costs and benefits of an early access scheme for oncology medicines in IrelandSemantic proximity Read

Methodological Challenges in Dutch HTA of Non-Oncological Orphan Drugs: A Retrospective Analysis and Price Comparison Using different Pricing ModelsSemantic proximity Read

Free of charge medicine schemes in the NHS. A local and regional Drug and Therapeutic Committees (DTC) experience.Semantic proximity Read

The Net Financial Benefits of Single Vendor Integrated CDMO and CRO Drug Development ServicesSemantic proximity Read

The WERA Cancer Center Matrix: Strategic Management of Patient Access to Precision Oncology in a Large and Mostly Rural Area of GermanySemantic proximity Read

Global Inequities in Precision Oncology Drug Development: A Cross-Sectional Analysis of FDA Approvals Between 2017-2024Semantic proximity Read

Does The Reformed Cancer Drug Fund Generate Evidence On Effectiveness? A Cross-sectional Analysis On Publicly Accessible DocumentationSemantic proximity Read

Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patientsSemantic proximity Read

The organization of clinical trials for oncology at IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale" Napoli and the impact of the OECI accreditation process.Semantic proximity Read

Access to Essential and Innovative Anti-cancer Medicines: A Longitudinal Study in Nanjing, ChinaSemantic proximity Read

How the HTAR will contribute to a value-based decision making for medicinal products across the EUSemantic proximity Read

Assessing the Value of Integrated Evidence Approaches in Drug DevelopmentSemantic proximity Read